Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529204 · ClinicalTrials.gov registry record · Phase 2
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
A Phase 2 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00529204 is a Phase 2 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 1 participants.
The verdict
NCT00529204, a Phase 2 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common complications of type 2 diabetes and leading causes of liver disease in the US and Europe. The prevalence of NAFLD and NASH are expected to become a major cause of liver disease related deaths and liver transplantation. Currently, there are no specific therapies that alter the natural history of NAFLD.Preliminary evidence suggests that exenatide (Byetta®) may have several beneficial direct and indirect effects on NAFLD and liver lipid metabolism.
Interventions
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529204
The ClinicalTrials.gov registry entry for NCT00529204 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which exenatide is the first listed.
NCT00529204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529204 about?
NCT00529204 is a clinical study titled "Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease". Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common complications of type 2 diabetes and leading causes of liver disease in the US and Europe. The prevalence of NAFLD and NASH are expected to become a major cause of liver disease related deaths and liver tra...
What is the current status of trial NCT00529204?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2007-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00529204?
The interventions under investigation include: exenatide (DRUG).
Who is sponsoring clinical trial NCT00529204?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.